US equities |
SPCX $166.94 ▲+5.02% NVDA $236.25 ▲+0.98% MU $1,063.21 ▼-1.09% TSLA $377.64 ▲+1.90% MSFT $524.94 ▲+1.43% SNDK $1,706.54 ▼-0.78% INTC $117.11 ▼-1.86% META $742.71 ▲+2.01%
FinancialContent

Innate Pharma S.A. - American Depositary Shares (NQ:IPHA)

1.532 -0.028 (-1.76%)
Delayed Quote Updated: 11:03 AM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Innate Pharma S.A. - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
News headline image
Innate Pharma Announces Its Participation in Upcoming Investor Conferences
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Highlights Abstracts Selected for ASCO 2024 Annual Meeting
From Innate Pharma SA
Via Business Wire
News headline image
Outcome of Innate Pharma’s 2024 Annual General Meeting
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma: Clarification Regarding SAR443579 Designation
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Highlights Abstracts Selected for EHA 2024 Congress
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Reports First Quarter 2024 Business Update and Financial Results
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Announces Conference Call and Webcast for Q1 2024 Business Update
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Announces Advancement of Sanofi-developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Announces Its Participation in Upcoming Investor Conference
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Files Its 2023 Universal Registration Document (Document d’enregistrement Universel) and 2023 Annual Report on Form 20-F
From Innate Pharma SA
Via Business Wire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Innate Pharma Reports Full Year 2023 Financial Results and Business Update
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Announces Its Participation to Upcoming Investor Conference
From Innate Pharma SA
Via Business Wire
News headline image
Earnings Scheduled For March 21, 2024 ↗
Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is expected to report quarterly earnings at $0.02 per share on revenue of $16.47 million. 
Via Benzinga
News headline image
Innate Pharma Announces Conference Call and Webcast for Full Year 2023 Financial Results
From Innate Pharma SA
Via Business Wire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
Innate Pharma to Present Nectin-4 Antibody Drug Conjugate IPH45 Preclinical Data at AACR 2024
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma: First Patient dosed in Phase 1/2 study of IPH6501 in relapsed /refractory B-Cell non-Hodgkin’s Lymphoma
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Announces Its Participation to Upcoming Investor Conference
From Innate Pharma SA
Via Business Wire
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Number of Shares and Voting Rights of Innate Pharma as of January 1, 2024
From Innate Pharma S.A.
Via Business Wire
News headline image
Innate Pharma Announces U.S. FDA Lifts Partial Clinical Hold on Lacutamab Clinical Program
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Strengthens Leadership and Appoints Two New Members to Its Executive Board
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Announces Licensing of a Fourth Natural Killer Cell Engager in Oncology to Sanofi
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Announces Leadership Change
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Shares Efficacy and Safety Phase 1 /2 Results of NK Cell Engager SAR443579 / IPH6101 Developed by Sanofi at ASH 2023
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Patients With Sézary Syndrome at ASH 2023
From Innate Pharma SA
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >